Skip to content

Trial Summary

This phase I trial is evaluating the safety and effectiveness of a new biological drug (CS1003) in patients with advanced cancers.

Acronym:

CS1003-101

ACTRN/NCT /ethics:

ACTRN12618000382279p

Scientific title:

A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors

Sponsor / Cooperative group:

Cstone

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date2018-05-09
Anticipated End Date2021-04-01

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Sarwan Bishnoi
Recruitment StatusRecruiting